NORFOLK, VA – September 29, 2010 – Genomind, LLC, a company specializing in neuropsychiatric personalized medicine, announced today the formation of its inaugural Scientific Advisory Board. The Scientific Advisory Board (SAB) consists of international thought leaders with in depth clinical and research experience in neuropsychiatric medicine.
The Board will initially be comprised of Scott T. Aaronson, MD, Director of Clinical Research at Sheppard Pratt, Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and Distinguished Fellow of the American Psychiatric Association; Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, at the Massachusetts General Hospital and Slater Family Professor of Psychiatry, Harvard Medical School; Roy H. Perlis, MD, Medical Director of the Bipolar Clinical and Research Program and Director, Psychiatric Pharmacogenomics Program, at the Massachusetts General Hospital; and Stephen Stahl, MD, Adjunct Professor of Psychiatry at the University of California San Diego and Chairman of the Neuroscience Education Institute.
“I am pleased to welcome these distinguished and well respected individuals to the Genomind Scientific Advisory Board,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind, LLC. “They bring a great wealth of knowledge and clinical experience to the company. Their contributions will further strengthen the company’s mission of bringing personalized medicine to psychiatry and to patients in need.”
About Genomind, LLC
Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by assisting physicians in the selection of appropriate medicine based on genetic information. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at: www.genomind.com.
